How can psychedelics for alcoholism treatment fundamentally alter our approach to recovery? In this episode of Gaia News, Dr. Ben Sessa of Awakn Life Sciences discusses how recent clinical trials for psychedelics are challenging conventional addiction medicine.
For decades, conventional treatments for alcohol use disorder have struggled with high relapse rates, leaving many seeking more sustainable paths to healing. Emerging psychedelic research on addiction suggests that integrating these substances into clinical settings can address the root psychological causes of substance abuse rather than just managing symptoms. By examining the efficacy of psychedelics on substance abuse, researchers are uncovering new pathways for neuroplasticity and emotional processing that traditional therapies often miss. This scientific shift represents a profound evolution in how we understand the relationship between brain chemistry, trauma, and habitual behavior, offering hope to those who have found little success with traditional support groups or standard pharmaceutical options.
This episode of Gaia News, Season 6, Episode 21, focuses on the groundbreaking results of treating alcoholism with psychedelics, specifically highlighting the role of psychedelic-assisted therapy in preventing relapse. Dr. Sessa shares insights from recent trials demonstrating that ketamine, when paired with specialized psychotherapy, significantly reduces relapse rates compared to standard treatments. By combining pharmacological intervention with structured psychological support, this approach offers a holistic framework that addresses both the biological and emotional aspects of dependency. Rather than relying on lifelong management, this methodology aims to help individuals process underlying emotional blockages, establish healthier cognitive patterns, and reclaim agency over their lives.
Begin your exploration into the future of mental health and discover how these clinical breakthroughs are redefining recovery.
